Document is current
Any future updates will be listed below
-
Authors
Palanikumar, L. https://orcid.org/0000-0002-2639-0436
Karpauskaite, Laura https://orcid.org/0000-0002-4288-3396
Al-Sayegh, Mohamed https://orcid.org/0000-0003-3865-1688
Chehade, Ibrahim https://orcid.org/0000-0003-0816-7609
Alam, Maheen https://orcid.org/0000-0002-4848-0782
Hassan, Sarah https://orcid.org/0000-0001-8762-434X
Maity, Debabrata
Ali, Liaqat
Kalmouni, Mona https://orcid.org/0000-0002-4006-8857
Hunashal, Yamanappa
Ahmed, Jemil
Houhou, Tatiana
Karapetyan, Shake
Falls, Zackary https://orcid.org/0000-0003-4116-0441
Samudrala, Ram https://orcid.org/0000-0001-9069-8497
Pasricha, Renu https://orcid.org/0000-0002-9659-1225
Esposito, Gennaro
Afzal, Ahmed J. https://orcid.org/0000-0003-1003-950X
Hamilton, Andrew D. https://orcid.org/0000-0002-0538-175X
Kumar, Sunil https://orcid.org/0000-0001-5472-4619
Magzoub, Mazin https://orcid.org/0000-0003-3414-6617
-
Funding
Funding for this research was provided by:
New York University Abu Dhabi (Research Grant)
- License Information
-
More Information
Article History
Received: 13 August 2020
Accepted: 26 May 2021
First Online: 25 June 2021
Competing interests
: New York University and New York University Abu Dhabi hold a patent for the use of oligopyridylamides to inhibit mutant p53 amyloid formation, with S. Kumar, A.D.H., M.M. and S.H. listed as inventors (US10500197B2).
